<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180463</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-IMIMH-05</org_study_id>
    <nct_id>NCT03180463</nct_id>
  </id_info>
  <brief_title>The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells</brief_title>
  <official_title>The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study is to evaluate the safety and efficacy of human umbilical cord&#xD;
      mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized,double-blind, paralleled study. Patients will be divided into two groups&#xD;
      of experiment and control. All of them will receive core decompression of the femoral head,&#xD;
      while experimental group patient will transplant hUC-MSC in addition. Follow-up visit will&#xD;
      occur on 1 month, 3 months, and 6 months after operation, and Harris Hip score was applied to&#xD;
      evaluate the symptoms change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Others&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI imageological examination</measure>
    <time_frame>6 months</time_frame>
    <description>MRI imageological examination to evaluate the efficient of mesenchymal stem cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate curative effects by the change of Harris hip score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteonecrosis of Femoral Head</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Core decompression surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)</intervention_name>
    <description>Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core decompression</intervention_name>
    <description>The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ficat classification is I, IIa, or IIb period&#xD;
&#xD;
          -  no obvious improvement or ingravescence by conservative treatment&#xD;
&#xD;
          -  patients or their statutory receive human umbilical cord mesenchymal stem cell of&#xD;
             their own will, and signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ficat classification is third or fourth period&#xD;
&#xD;
          -  acute, chronic infection patients&#xD;
&#xD;
          -  combined with heart, lung, kidney disease, and cannot tolerate operation&#xD;
&#xD;
          -  ankylosing spondylitis patient&#xD;
&#xD;
          -  acetabular dysplasia patient&#xD;
&#xD;
          -  with tumor&#xD;
&#xD;
          -  clinical data deficient&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  pregnancy or breast feeding women&#xD;
&#xD;
          -  under other therapy that possibly influence MSC security or efficacy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bahushan</last_name>
    <role>Study Director</role>
    <affiliation>Inner Mongolia International Mongolian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Guo, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>China-Japan Union Hospital, Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inner Mongolia International Mongolian Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteonecrosis of Femoral Head</keyword>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

